Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Down 99.4% in January

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 97,300 shares, a drop of 99.4% from the January 15th total of 15,930,000 shares. Based on an average daily trading volume, of 1,530,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.7% of the company’s shares are sold short.

Tonix Pharmaceuticals Trading Up 2.2 %

Shares of Tonix Pharmaceuticals stock traded up $0.25 during trading hours on Thursday, hitting $11.75. The company’s stock had a trading volume of 436,537 shares, compared to its average volume of 1,512,399. The company has a market capitalization of $21.97 million, a PE ratio of 0.00 and a beta of 2.07. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a 50 day moving average of $29.24 and a 200 day moving average of $25.22. Tonix Pharmaceuticals has a 12 month low of $10.82 and a 12 month high of $1,248.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, topping the consensus estimate of ($203.00) by $180.00. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Analysts predict that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a report on Monday. They set a “sell” rating for the company.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth about $40,000. PFG Investments LLC acquired a new position in Tonix Pharmaceuticals during the 4th quarter worth approximately $72,000. Finally, Geode Capital Management LLC grew its stake in shares of Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after acquiring an additional 1,855,907 shares in the last quarter. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.